Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs OMTRYG
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Treatment of chronic hepatitis C virus (HCV) genotype 4 infection without cirrhosis or with compensated cirrhosis,Treatment of chronic HCV genotype 1 infection (with ribavirin or as part of combination therapy)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (Cr Cl <30 m L/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Ombitasvir: primarily metabolized by CYP3A4; Paritaprevir: primarily metabolized by CYP3A4; Ritonavir: primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
38-45%, primarily bound to albumin.
Approximately 95% bound to serum albumin.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and plasma with limited tissue penetration.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: 60-80% (first-pass effect); Subcutaneous: 90-100%.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No dose adjustment required for GFR ≥30 m L/min; avoid use if GFR <30 m L/min.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No dose adjustment required for Child-Pugh A or B; not recommended in Child-Pugh C due to lack of data.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
No dose adjustment required based on age; monitor for taste disturbance and renal function.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
WARNING: HEPATITIS B VIRUS REACTIVATION — Test all patients for evidence of current or prior HBV infection before initiating treatment. HBV reactivation has been reported in patients coinfected with HCV and HBV, which can result in fulminant hepatitis, hepatic failure, and death.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Risk of hepatitis B virus reactivation,Hepatic decompensation/hepatic failure in patients with cirrhosis,ALT elevations and hepatic injury,Risk of drug interactions (significant CYP3A4 inhibition),Use with ribavirin: ribavirin-related adverse effects (e.g., anemia, teratogenicity)
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Severe hepatic impairment (Child-Pugh C),Known hypersensitivity to ombitasvir, paritaprevir, ritonavir, or any component of the formulation,Coadministration with drugs highly dependent on CYP3A4 for clearance (e.g., alfuzosin, amiodarone, sildenafil when used for pulmonary arterial hypertension, ergot derivatives, lovastatin, simvastatin, midazolam, triazolam),Moderate to severe hepatic impairment in patients with cirrhosis (Child-Pugh B and C)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
No clinically significant food interactions reported.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, neonatal renal failure. Risk is dose-dependent.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Contraindicated during breastfeeding. M/P ratio not established; drug excreted into breast milk. Potential for serious adverse effects in nursing infant (renal toxicity).
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Not applicable; contraindicated in pregnancy. No dose adjustment recommended due to contraindication.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
OMTRYG (triptorelin pamoate) is a Gn RH agonist used for advanced prostate cancer. Monitor for tumor flare at therapy initiation; consider antiandrogen coadministration for first month. Baseline and periodic serum testosterone and PSA levels are essential. Caution in patients with spinal cord compression or urinary tract obstruction. Risk of QT prolongation; assess electrolytes and ECG in at-risk patients. Depot formulation provides 6-month coverage.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
OMTRYG is injected every 6 months by a healthcare provider.,You may experience a temporary increase in bone pain or urinary symptoms during the first few weeks.,Report new or worsening pain, difficulty urinating, or leg weakness immediately.,Hot flashes, decreased libido, and erectile dysfunction are common.,Do not stop treatment without consulting your doctor.,Keep all scheduled injections; missed doses can reduce effectiveness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs OMTRYG, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. OMTRYG is a HMG-CoA Reductase Inhibitor (Statin) that works by OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and OMTRYG depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of OMTRYG is: 2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and OMTRYG in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. OMTRYG is classified as Category C. Pregnancy Category X: contraindicated in pregnancy. First trimester: major congenital malformations (e.g., neural tube defects, cardiac anomalies). Second and third trimesters: fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.